Lapatinib: A sword with two edges

Pathology and Oncology Research

Volumn 14, Issue 1, 2008, Pages 1-8

  Kopper, László ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Breast cancer; EGFR inhibition; HER2 inhibition; Lapatinib; Targeted therapy; Trastuzumab resistency

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; INCB 7839; IRINOTECAN; LAPATINIB; LAPATINIB PLUS PAZOPANIB; OXALIPLATIN; PACLITAXEL; PROTEIN INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADENOID CYSTIC CARCINOMA; BRAIN METASTASIS; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INHIBITION; GASTROINTESTINAL TOXICITY; GLIOMA; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; RASH; REVIEW; SALIVARY GLAND TUMOR; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; UTERINE CERVIX CANCER; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 41949125812     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-008-9018-z     Document Type: Review

References (38)

1. D Bilancia G Rosati A Dinota 2007 Lapatinib in breast cancer Ann Oncol 18 suppl 6 vi26 vi30
2. PM Harari GW Allen JA Bonner 2007 Biology of interactions: antiepidermal growth factor receptor agents J Clin Oncol 25 4057 4065
3. ER Wood AT Truesdale OB Mc Donald 2004 A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res 64 6652 6659
4. W Xia LH Liu P Ho NL Spector 2004 Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016 Oncogene 23 646 653
5. DW Rusnak K Lackey K Affleck 2001 The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo Mol Cancer Ther 1 85 94
6. I Chu K Blackwell S Chen J Slingerland 2005 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer Cancer Res 65 18 25
7. HA Burris HI Hurwitz C Dees 2005 Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases in heavily pretreated patients with metastatic carcinomas J Clin Oncol 23 5305 5313
8. Blackwell KL, Burstein H, Pegram M, et al (2005) Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. Proc Am Soc Clin Oncol 23:(abstr 3004)
9. QSC Chu G Schwartz J de Bono 2007 Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced malignancies J Clin Oncol 25 3753 3758
10. WS Siegel-Lakhai JH Beijnen WL Vervenne 2007 Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors Clin Cancer Res 13 4495 4502
11. RS Midgley DJ Kerr KT Flaherty 2007 A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan Ann Oncol 18 2025 2029
12. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene Science 235 177 182
13. A Magnifico L Albano S Campaner 2007 Protein kinase C determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification Cancer Res 67 5308 5317
14. CL Vogel MA Cobleigh D Tripathy 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726
15. PS Hegde D Rusnak M Bertiaux K Alligood J Strum R Gagnon TM Gilmer 2007 Delineation of molecular mechanisms of sensitivity to lapitinib in breast cancer cell lines using global gene expression profiles Mol Cancer Ther 6 1629 1640
16. B Moy P Kirkpatrick S Kar P Goss 2007 Lapatinib Nature Rev Drug Discovery 6 431 432
17. W Xia CM Gerard L Liu NM Baudson TL Ory NL Spector 2005 Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells Oncogene 24 6213 6221
18. Spector N, Liu L, Gerard C et al (2005) Combining lapatinib (GW572016) with anti-erbB2 antibodies elicits synergistic apoptotic effects in erbB2 overexpressing breast cancer cells. J Clin Oncol 23(16S, pt1), abstract 557
19. GE Konecny MD Pegram N Venkatesan 2006 Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2 overexpressing and trastuzumab-treated breast cancer cells Cancer Res 66 1630 1639
20. Storniolo AM, Burris HA, Overmoyer B et al (2005) A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. Breast Cancer Res Treat 2005:94(suppl 1), abstract 1073
21. Palmieri D, Gril BM, Herring J et al (2007) Lapatinib prevents the metastatic colonization of EGFR+ and HER2+ breast cancer cells in the brain. Breast Cancer Res Treat suppl 1, abstract 210
22. CE Geyer J Forster D Lindquist 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer New Engl J Med 355 2733 2743
23. NU Lin LA Carey MC Liu 2006 Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer J Clin Oncol 24 18S
24. EA Perez 2006 Cardiac safety experience in 3127 patients treated with lapatinib Ann Oncol 17 Suppl 9 A1420
25. Cameron D, Casey M, Press M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat (in press) doi: 10.1007/s10549-007-9885-0
26. RS Tuma 2007 Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials J Natl Cancer Inst 99 348 349
27. NL Spector K Blackwell J Hurley 2006 EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response J Clin Oncol ASCO Annual Meeing Procs Part I 24 18S
28. M Cristofanilli H Boussen J Baselga 2006 A phase II combination study of lapatinib and paclitaxel as a therapy in patients with newly diagnosed inflammatory breast cancer (IBC) Breast Cancer Res Treat 100 suppl 1 S5
29. R Nahta LXH Yuan B Zhang R Kobayashi FJ Esteva 2005 Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells Cancer Res 65 1118 1125
30. R Nahta LXH Yuan Y Du FJ Esteva 2007 Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling Mol Cancer Ther 6 667 674
31. W Xia S Bacus P Hegde 2006 A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer Proc Natl Acad Sci USA 103 7795 7800
32. MP DiGiovanna A Chakraborty 2006 Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: dramatic effects of HER2 inhibitors on non-overexpressing cells Proc Am Assoc Cancer Res 47 1226
33. Witters LM, Scherle PA, Friedman SM et al (2007) Inhibition of breast cancer growth with the combination of lapatinib and an ADAM protease inhibitor. Breast Cancer Res Treat 106(suppl 1), abstract 1117
34. MJ Piccart-Gebhart EA Perez J Baselga 2007 ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study (BIG 2-06/N063D/EGF106708): a phase III study for HER2-overexpressing breast cancer (BC) Breast 16 suppl 1 S46
35. Frassoldati A, Guarneri V, Cagossi K et al (2007) LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breast cancer. Preliminary report of activity and cardiac tolerability. Breast Cancer Res Treat (suppl 1), abstract 2087
36. LA McHugh M Kriajevska JK Mellon TR Griffiths 2007 Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens-evidence of schedule-dependent synergy Urology 69 390 394
37. M Agulnik WE Ezra RB Cohen 2007 Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands J Clin Oncol 25 3978 3984
38. C Widakowich E de Azambuja T Gil 2007 Molecular targeted therapies in breast cancer: where are we now? Internat J Biochem Cell Biol 39 1375 1387